Explore our company news, announcements and updates
December 4, 2025
FDA Conditionally Approves Merck Animal Health’s EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
Mexico’s SADER Approves Merck Animal Health’s EXZOLT® 5% Pour-On (Fluralaner 50 mg/mL) for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (Myiasis)
New Data from Merck Animal Health Demonstrates that Intranasal Vaccination Against Bovine Coronavirus with BOVILIS® NASALGEN®-C (Lyophilisate and Solvent for Suspension for Cattle) Significantly Improves Production in Veal Calves
Merck Animal Health Presents New Data Demonstrating the Safety, Efficacy and Quick Onset of Injectable Formulation of BRAVECTO® (fluralaner) at World Small Animal Veterinary Association Congress
Merck Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress
Merck Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen